Non-Hodgkin Lymphoma Clinical Trials

67 studies are recruiting for non-hodgkin lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

   Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned stu…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Sylvester Comprehensive Cancer Center, Miami, Florida

   Locations

   36 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06876662 on ClinicalTrials.gov

2. Study of SGR-1505 in Mature B-Cell Neoplasms

   The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Banner Health - MD Anderson Cancer Center, Gilbert, Arizona

   Locations

   36 in total

   Run by

   Schrödinger, Inc.

   See if you can join NCT05544019 on ClinicalTrials.gov

3. In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

   The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans ce…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05093335 on ClinicalTrials.gov

4. Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families

   This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders.

   Stage

   Not phased

   Ages

   Up to 22

   Site

   Children's Hospital Colorado, Aurora, Colorado

   Run by

   University of Colorado, Denver

   See if you can join NCT05425992 on ClinicalTrials.gov

5. Lifestyle Intervention of Food and Exercise for Lymphoma Survivors

   The purpose of this study is to investigate if a mediterranean diet and exercise program for Lymphoma patients during chemotherapy can improve treatment completion and reduce treatment-related side effects.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT05839210 on ClinicalTrials.gov

6. Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

   The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.

   Stage

   Not phased

   Ages

   Any age

   Site

   Ut Southwestern, Dallas, Texas

   Locations

   8 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06357754 on ClinicalTrials.gov

7. PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy

   This is a phase I/Ib imaging study of granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64Cu-GRIP B) Positron Emission Tomography (PET) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) receiving CD19-directed Chimeric antigen recep…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Michael Randall

   See if you can join NCT06522932 on ClinicalTrials.gov

8. Amping up With PemJAK

   The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.

   Stage

   Phase 2

   Ages

   18 to 95

   Site

   Columbia University Irving Medical Center, New York, New York

   Run by

   Seda S. Tolu

   See if you can join NCT07283822 on ClinicalTrials.gov

9. AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

   This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC Irvine Health, Orange, California

   Locations

   13 in total

   Run by

   Carna Biosciences, Inc.

   See if you can join NCT05602363 on ClinicalTrials.gov

10. Mozobil for Autologous Hematopoietic Stem Cell Transplantation

    This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

    Run by

    Thomas Jefferson University

    See if you can join NCT07188090 on ClinicalTrials.gov

11. A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

    This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Kansas, Westwood, Kansas

    Locations

    7 in total

    Run by

    CRISPR Therapeutics AG

    See if you can join NCT05643742 on ClinicalTrials.gov

12. Auto Stem Cell Transplant for Lymphoma Patients

    This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

    Stage

    Phase 2

    Ages

    Up to 75

    Site

    Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT03125642 on ClinicalTrials.gov

13. Two Step Haplo With Radiation Conditioning

    This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however th…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia, Pennsylvania

    Run by

    Thomas Jefferson University

    See if you can join NCT05031897 on ClinicalTrials.gov

14. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Birmingham, Alabama

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

15. Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

    This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Stanford University, Palo Alto, California

    Run by

    Stanford University

    See if you can join NCT05794958 on ClinicalTrials.gov

16. Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

    The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (c…

    Stage

    Phase 2

    Ages

    3 to 39

    Site

    University of Flordia, Gainsville, Florida

    Locations

    3 in total

    Run by

    New York Medical College

    See if you can join NCT05253495 on ClinicalTrials.gov

17. Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

    This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Goshen Center for Cancer Care, Goshen, Indiana

    Locations

    45 in total

    Run by

    Kartos Therapeutics, Inc.

    See if you can join NCT04502394 on ClinicalTrials.gov